|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||49.99 - 51.12|
|52 Week Range||45.24 - 60.49|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||1.70|
|Expense Ratio (net)||0.59%|
Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter—compared to revenues of $5.773 billion during the third quarter of 2017. The EPS is estimated to be $3.45 for the third quarter—compared to the EPS of $3.27 for the third quarter of 2017.
Biogen (BIIB), a leading biotechnology company, released its third-quarter earnings on October 23. Biogen surpassed Wall Street analysts’ estimates for EPS and revenues during the quarter. Biogen reported non-GAAP diluted EPS of $7.40 on revenues of ~$3.44 billion.
As we discussed in the previous part, analysts expect Biogen’s (BIIB) revenues to increase 8.3% to $3.33 billion during the third quarter. Biogen’s product portfolio includes multiple sclerosis products, spinal muscular atrophy products, biosimilars, and other products. Biogen’s portfolio also includes Anti-CD20 therapeutic programs.
Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017. Also, the company is estimated to report a net adjusted loss of $29.9 million during 2018 as compared to a net adjusted loss of $5.9 million during 2017, following the increase in selling, general, and administrative expenses as well as research and development expenses. The adjusted earnings per share for 2018 are estimated to come in at -$0.08 per share.
Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. As of August 6, 19 analysts were tracking Sarepta Therapeutics stock.
What Do Analysts Expect from Ionis’s Second-Quarter Earnings? Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017. Ionis’s stock price has decreased by nearly 14.5% over the last 12 months and decreased by ~14.3% in 2018 year-to-date.
Biotechnology sector ETFs were among the best performers Tuesday, with Illumina (ILMN) shares surging after the genomics firm beat second-quarter expectations and raised its year-end outlook. Among the best performing ETFs of Tuesday, the Invesco Dynamic Biotech & Genome (PBE) increased 3.0%, ARK Genomic Revolution Multi-Sector ETF (ARKG) advanced 2.5% and iShares Nasdaq Biotechnology ETF (IBB) rose 2.0%. Evercore analyst Ross Muken said in that the Illumina stock story is "far too compelling to ignore," reports Allison Gatlin for Investor's Business Daily.
Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases. The chart below compares Ionis’s revenue and EPS since Q1 2017. In the first quarter, Ionis’s revenue rose ~24.7% year-over-year to $144.4 million from $115.8 million.
As we discussed earlier, Ionis Pharmaceuticals (IONS) is one of the leading biopharmaceutical companies focused on discovering, developing, and commercializing RNA-targeted (ribonucleic acid) therapies. Ionis has created a drug discovery platform and developed many drugs for the treatment of various life-threatening diseases through this broadly applicable platform. Ionis’s revenue sources include its commercial revenue, including its Spinraza royalties and licensing and royalty revenues, and its research and development revenue under its collaborative agreements.